Genmab and argenx combine antibody know-how

Genmab A/S and argenx will start their collaboration jointly launching two antibody programmes in immunology and oncology with the potential to expand to more. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of first-in-class antibody candidates in oncology, immunology and inflammation.

According to the agreement, argenx and Genmab will each have access to the suites of proprietary antibody technologies of both companies to advance the identification of leads against disease targets. Under the terms of the agreement, argenx and Genmab will jointly discover, develop and commercialise products emerging from the collaboration while equally sharing costs as well as any potential future profits.

Genmab’s pipeline includes bispecific T-cell engagers, next-ge immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.  argenX markets the first-and- only approved neonatal Fc receptor (FcRn) blocker in the US, Japan, and the EU. The company is evaluating efgartigimod in several autoimmune diseases .